ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2seventy bio Announces Upcoming Investor Events

September 13, 2021 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 13, 2021--

2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy.

  • Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DARIC33] and Next-Gen Multiple Myeloma Strategy
    • September 21, 2021, 11:00am-12:00pm ET
  • Session Two: Focus on bNHL [bbT369] and Solid Tumor Strategy
    • September 22, 2021, 1:00-2:00pm ET

To access the live webcasts and dial-in information for 2seventy bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210913005440/en/

CONTACT: Investors & Media

Investors:

Elizabeth Pingpank, 617-914-8736

epingpank@bluebirdbio.com

Media:

Jenn Snyder, 617-448-0281

jsnyder@bluebirdbio.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: RESEARCH FDA GENETICS BIOTECHNOLOGY HEALTH GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY

SOURCE: bluebird bio

Copyright Business Wire 2021.

PUB: 09/13/2021 08:00 AM/DISC: 09/13/2021 08:06 AM

http://www.businesswire.com/news/home/20210913005440/en